From the Professor..., page-95

That's like saying the global FTO inhibitor market is $0. I'm sure you would agree that such a figure is meaningless to someone looking to disrupt the broader oncology market.

Imugene isn't targeting the current OV market alone with Vaxinia and onCARlytics. They're going after many solid tumour types with markets outside current OV therapies.

Would be more meaningful to look at market size of target tumour types. Start with cholangiocarcinoma ($400-700m). Hopefully add HNSCC and melanoma. And fingers crossed for others - TNBC? Ovarian? Etc etc.

And of course blood cancers with Azer-Cel.